Viewing Study NCT07332351

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:18 PM
Ignite Modification Date: 2026-05-28 @ 8:07 PM
Study NCT ID: NCT07332351
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-13
First Post: 2026-01-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
Sponsor: University of Washington
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Muscle Invasive Bladder Urothelial Carcinoma View
None Stage II Bladder Cancer AJCC v8 View
None Stage IIIA Bladder Cancer AJCC v8 View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Urinary Bladder View